Fee4GrannyLa

FLOCK THIS! When those in power cannot defend their actions, they attempt to discredit the people asking questions. During COVID, skeptics were called conspiracy theorists. Now, citizens questioning mass surveillance are being labeled extremists and terrorists. A free nation requires honest debate, complete transparency, and citizens who have the courage to question authority. We must never allow loaded labels to replace facts or become weapons against the American people. Glenn Jacobs is exactly right.

"Big turnout for BirdFlu Vaccine Protest in Canberra.😜 Well done to whoever put this together, but when there are approximately one billion individual wild birds in Australia across roughly 800 to 900 species - anyone who thinks they are saving the birds by injecting them is totally cooked." https://fixupx.com/craigkellyAFEE/status/2088866601068269633

https://fxtwitter.com/FeeRedfern/status/2088895751804088513?s=20

https://salutedigitale.blog/2024/01/22/la-sanita-digitale-tra-tolomeo-copernico-e-ulisse/

https://salutedigitale.blog/2021/11/01/il-garante-privacy-a-caccia-di-app-pirata-per-la-verifica-del-green-pass-e-quelle-ufficiali-degli-altri-paesi-europei/

https://salutedigitale.blog/2020/04/06/perche-le-app-da-sole-non-sono-la-panacea-per-la-lotta-al-coronavirus/

https://salutedigitale.blog/2020/03/13/il-contributo-della-salute-digitale-nella-lotta-al-coronavirus/

https://salutedigitale.blog/2020/01/28/sviluppato-il-primo-kit-lab-on-chip-per-rilevare-il-wuhan-coronavirus/

https://bfakhoury.com/danse-gwenedour/

For those interested, a (human supervised) ChatGPT generated review article of all my substack articles discussing the miscarriage risk.

Paul Feldman, chief executive, Jisc, champions digital technology in education and research. https://web.archive.org/web/20251119092027/https://www.thetimes.com/business/companies-markets/article/britains-500-most-influential-fxtzx0sg7qd Paul Feldman Formerly Chief Executive of JISC Dr. Paul Feldman was the chief executive of Jisc, the UK’s digital body for tertiary education, research and innovation, a position he took up in mid-October 2015, which he transformed into a trusted powerhouse of infrastructure, cyber security, solutions and advice. He is now supporting HE and research on a number of governing bodies/boards of institutions and agencies. Prior to Jisc, Paul was an executive partner at Gartner UK, a technology research and advisory firm. He spent over 20 years in financial services at Nationwide Building Society, Barclays Bank and First Data EMEA, both in IT and business roles. He has also worked in knowledge-based IT companies including Thomson Reuters Legal UK and the Intellectual Property Office. Paul has a track record in introducing innovative solutions, was in the vanguard of the first moves to use the internet for commercial purposes and led the work that resulted in same-day payments between bank accounts. https://oxfordacademy.org.uk/wp-content/uploads/2025/07/Paul-Feldman.pdf Delivery of Advanced Network to Europe Limited (Geant Ltd) Geant: Development Of Advanced Electronic Telecommunication Facilities, Cambridge https://find-and-update.company-information.service.gov.uk/officers/4BUKnjfwMY5n0EI12EkBPE0kx0o/appointments https://www.heanet.ie/who-we-are/governance/paul-feldman

MAGIC (Middleware for collaborative Applications and Global Virtual Communities – Project number: 654225) is a project co-funded by the European Commission within the Horizon 2020 Programme (H2020), Directorate General for Communications Networks, Content and Technology - eInfrastructure. MAGIC began on 1st May 2015 and will run for 24 months. For more information on MAGIC, its partners and contributors please see http://www.magic-project.eu Guidelines, objective, directives and strategic work plan of the MAGIC Global Science Communities Building on the ELCIRA project, RedCLARA Latin America, Europe, the Caribbean, West and Central Africa, Eastern and Southern Africa, North Africa and the Middle East, Central Asia and Asia-Pacific- is leading MAGIC, aims to significantly improve the ability of researchers and academics around the world to collaborate together web.archive.org/web/20170603021911/http://magic-project.eu/index.php/about/about-magic Geant Ltd et al cordis.europa.eu/project/id/654225/

Source: EU Project Manager: UNIVERSITY OF CAPE TOWN Project Number: 101103076 Application Type: HORIZON JU Research and Innovation Actions / HORIZON-JU-RIA Project Period: 2023 - 2027 Funding received from: Organisation: Øvrige / Øvrige andre / MAGIC - MAKING GRADE THE IRRESISTIBLE CHOICE Location: Oslo - Oslove / Oslo - Oslove Mitigating Antimalarial Resistance Consortium in South-East Africa STICHTING AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT Netherlands Net EU contribution € 220 750,00 KAROLINSKA INSTITUTET Sweden Net EU contribution € 109 812,50 STIFTELSEN MAGIC EVIDENCE ECOSYSTEM Norway Net EU contribution € 299 800,00 THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD United Kingdom Net EU contribution € 781 657,50 UNIVERSITY OF RWANDA Rwanda Net EU contribution € 373 201,25 LINQ MANAGEMENT GMBH Germany Net EU contribution € 356 312,50 LIVERPOOL SCHOOL OF TROPICAL MEDICINE United Kingdom Net EU contribution € 793 456,25 INFECTIOUS DISEASES RESEARCH COLLABORATION LTD BY GUARANTEE Uganda Net EU contribution € 359 020,35 PARTNER UNIVERSITY OF MELBOURNE Australia https://cordis.europa.eu/project/id/101103076 https://prosjektbanken.forskningsradet.no/en/project/EU/101103076?distribution=Ar&chart=bar&calcType=projects&Sprak=no&sortBy=score&sortOrder=desc&resultCount=30&offset=0&Fritekst=MAGICapp

https://archive.is/DLorg

10 December 2018 News CEPI and Imperial College London collaborate on Disease X vaccines project Disease X vaccine project focuses on known and unknown pathogens New saRNA vaccine platform is expected to transform regional and global preparedness against Disease X outbreaks. Credit: Imperial College London. The Coalition for Epidemic Preparedness Innovations (CEPI) in Norway and Imperial College London have formed an alliance to develop new vaccines against known as well as unknown pathogens, which are commonly referred to as Disease X. Under the $8.4m project, the partners will create a synthetic, self-amplifying RNA (saRNA) vaccine platform called RapidVac for the quick development of vaccines. The saRNA technology will leverage the body’s own cell system to make an antigen in order to trigger an immune response, rather than directly injecting the antigen. Development of vaccines currently takes approximately ten years, however, the new collaboration aims to cut this time to a total of 16 weeks – from identification of antigen to release of the product for clinical trials. Imperial College London Mucosal Infection and Immunity chair Robin Shattock said: “We believe that synthetic self-amplifying RNA based vaccines offer the best opportunity for a ‘just in time’ response to infectious outbreaks, providing the needed technological shift to aggressively redefine the timelines for vaccine production.” Imperial will lead a consortium to create the RapidVac platform, which will be used to generate vaccines to protect from influenza (H1N1), rabies and Marburg viruses. The partners expect the new vaccine platform to aid both regional and global preparedness against outbreaks of Disease X by allowing rapid production of large volumes of ‘single-shot’ and ‘cocktail’ vaccines within weeks. How serious a threat to global health do you think the Wuhan coronavirus outbreak is? A very minor threat A relatively minor threat A significant threat A serious threat An extremely serious threat “We cannot predict where or when Disease X will strike, but by developing these kinds of innovative vaccine technologies we can be ready for it.” https://web.archive.org/web/20200207104302/https://www.pharmaceutical-technology.com/news/disease-x-vaccines-project/

About Micron Biomedical https://cepi.net//cepi-and-micron-biomedical-accelerate-needle-free-vaccines-against-disease-x Micron Biomedical is the leader in dissolvable microarray-based, drug and vaccine administration technology. Micron Biomedical is a clinical-stage life science company on a rapid path to commercializing its proprietary dissolvable, microarray technology. Micron’s technology is designed to improve access and achieve better health outcomes globally through injection-free, painless, and simple and/or self-administration of drugs and vaccines, and by eliminating or reducing the need for cold chain transport and storage, enhancing safety and efficacy, and improving patient compliance. Micron partners with and/or receives funding from private and public pharmaceutical and biotech companies, the Bill & Melinda Gates Foundation, the Centers for Disease Control and Prevention (CDC), PATH and the Georgia Research Alliance. For more information visit www.micronbiomedical.com

https://www.lshtm.ac.uk/newsevents/events/advances-disease-x-preparedness

https://jwilderness.substack.com/p/disease-x-and-cepis-propaganda-manual

https://static.cepi.net/downloads/2026-07/CEPI%202025%20Annual%20Progress%20Report_FINAL.pdf

https://static.cepi.net/downloads/2025-07/CEPI%202024%20APR%20Report%20FINAL%20-%20V3.pdf